Adverse Events of Adjuvant Mitotane Treatment for Adrenocortical Carcinoma.
Adjuvant treatment
adrenal insufficiency
adrenocortical carcinoma
adverse event
hydrocortisone replacement
mitotane
Journal
Endocrine research
ISSN: 1532-4206
Titre abrégé: Endocr Res
Pays: England
ID NLM: 8408548
Informations de publication
Date de publication:
15 Sep 2024
15 Sep 2024
Historique:
medline:
15
9
2024
pubmed:
15
9
2024
entrez:
15
9
2024
Statut:
aheadofprint
Résumé
Mitotane is the cornerstone of adjuvant adrenocortical cancer (ACC) treatment. However, its use is burdened with frequent adverse events. A retrospective analysis of adverse events was performed in 26 ACC patients adjuvantly treated with mitotane. Mitotane toxicity was present in all patients (100%). Two (7.7%) patients developed 1-3 adverse events, 15 (57.7%) experienced 4-6 adverse events and 9 (34.6%) patients had more than 6 adverse events. Two (7.7%) patients discontinued mitotane due to adverse events. Careful monitoring and timely management are essential for ensuring mitotane treatment adherence and maximizing its benefits.
Sections du résumé
BACKGROUND
UNASSIGNED
Mitotane is the cornerstone of adjuvant adrenocortical cancer (ACC) treatment. However, its use is burdened with frequent adverse events.
METHODS
UNASSIGNED
A retrospective analysis of adverse events was performed in 26 ACC patients adjuvantly treated with mitotane.
RESULTS
UNASSIGNED
Mitotane toxicity was present in all patients (100%). Two (7.7%) patients developed 1-3 adverse events, 15 (57.7%) experienced 4-6 adverse events and 9 (34.6%) patients had more than 6 adverse events. Two (7.7%) patients discontinued mitotane due to adverse events.
CONCLUSION
UNASSIGNED
Careful monitoring and timely management are essential for ensuring mitotane treatment adherence and maximizing its benefits.
Identifiants
pubmed: 39277812
doi: 10.1080/07435800.2024.2402311
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM